Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndromeShow others and affiliations
2017 (English)In: Alzheimer's & Dementia: Journal of the Alzheimer's Association, ISSN 1552-5260, E-ISSN 1552-5279, Vol. 13, no 5, p. 541-549Article in journal (Refereed) Published
Abstract [en]
INTRODUCTION: Individuals with Down syndrome (DS) exhibit Alzheimer's disease (AD) neuropathology and dementia early in life. Blood biomarkers of AD neuropathology would be valuable, as non-AD intellectual disabilities of DS and AD dementia overlap clinically. We hypothesized that elevations of amyloid-β (Aβ) peptides and phosphorylated-tau in neuronal exosomes may document preclinical AD.
METHODS: AD neuropathogenic proteins Aβ1-42, P-T181-tau, and P-S396-tau were quantified by enzyme-linked immunosorbent assays in extracts of neuronal exosomes purified from blood of individuals with DS and age-matched controls.
RESULTS: Neuronal exosome levels of Aβ1-42, P-T181-tau, and P-S396-tau were significantly elevated in individuals with DS compared with age-matched controls at all ages beginning in childhood. No significant gender differences were observed.
DISCUSSION: These early increases in Aβ1-42, P-T181-tau, and P-S396-tau in individuals with DS may provide a basis for early intervention as targeted treatments become available.
Place, publisher, year, edition, pages
Elsevier, 2017. Vol. 13, no 5, p. 541-549
Keywords [en]
Alzheimer's disease, Amyloid-β, Blood biomarkers, Down syndrome, Hyperphosphorylated tau, Intellectual disability, Neuronal exosomes
National Category
Neurosciences
Research subject
Social Sciences, Psychology
Identifiers
URN: urn:nbn:se:lnu:diva-61278DOI: 10.1016/j.jalz.2016.08.012ISI: 000400554400005PubMedID: 27755974Scopus ID: 2-s2.0-85007392964OAI: oai:DiVA.org:lnu-61278DiVA, id: diva2:1080741
2017-03-102017-03-102023-03-28Bibliographically approved